Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI

SIMPLE SUMMARY: Neoadjuvant systemic therapy (NAST) is given before surgery to reduce tumor burden in patients with triple-negative breast cancer (TNBC), which is an aggressive breast cancer subtype that accounts for approximately 30% of breast cancer-related mortalities. Unfortunately, approximatel...

Descripción completa

Detalles Bibliográficos
Autores principales: Panthi, Bikash, Adrada, Beatriz E., Candelaria, Rosalind P., Guirguis, Mary S., Yam, Clinton, Boge, Medine, Chen, Huiqin, Hunt, Kelly K., Huo, Lei, Hwang, Ken-Pin, Korkut, Anil, Lane, Deanna L., Le-Petross, Huong C., Leung, Jessica W. T., Litton, Jennifer K., Mohamed, Rania M., Musall, Benjamin C., Pashapoor, Sanaz, Patel, Miral M., Perez, Frances, Son, Jong Bum, Thompson, Alastair, Valero, Vicente, Wei, Peng, White, Jason, Xu, Zhan, Pinsky, Lawrence, Tripathy, Debu, Yang, Wei, Ma, Jingfei, Rauch, Gaiane M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953797/
https://www.ncbi.nlm.nih.gov/pubmed/36831368
http://dx.doi.org/10.3390/cancers15041025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953797/
https://www.ncbi.nlm.nih.gov/pubmed/36831368
http://dx.doi.org/10.3390/cancers15041025

Ejemplares similares